Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

KINETICS OF SERUM AMINOSALICYLIC ACID LEVELS.

H ENGBERG-PEDERSEN, P MORCH, L TYBRING

    British Journal of Pharmacology and Chemotherapy
    |August 1, 1964
    PubMed
    Summary

    A mathematical model explains serum levels of p-aminosalicylic acid (PAS) after oral and IV administration. Different PAS preparations show varying blood levels explained by model parameters, with a second-order model needed for high IV doses.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Quantitative determination of 4-methylthiouracil in urine.

    Acta pharmacologica et toxicologica·2010
    Same author

    Guidelines for the statistical evaluation of SCE.

    Basic life sciences·1984
    Same author

    Statistics of the mouse bone-marrow micronucleus test: counting, distribution and evaluation of results.

    Mutation research·1983
    Same author

    Pivmecillinam and trimethoprim/sulfamethoxazole in the treatment of bacteriuria. A bacteriological and pharmacokinetic study.

    The Journal of antimicrobial chemotherapy·1979
    Same author

    Special aspects of laboratory investigations with mecillinam.

    The Journal of antimicrobial chemotherapy·1977
    Same author

    Mecillinam (FL 1060), a 6beta-amidinopenicillanic acid derivative: bactericidal action and synergy in vitro.

    Antimicrobial agents and chemotherapy·1975

    Area of Science:

    • Pharmacokinetics
    • Mathematical Modeling
    • Drug Metabolism

    Background:

    • Serum levels of p-aminosalicylic acid (PAS) vary with dosage and preparation.
    • Understanding PAS pharmacokinetics is crucial for effective tuberculosis treatment.

    Purpose of the Study:

    • To apply a mathematical model to explain observed serum levels of PAS.
    • To differentiate pharmacokinetic behavior of various PAS preparations.
    • To investigate PAS elimination kinetics under different administration routes and concentrations.

    Main Methods:

    • Utilized a three-consecutive-first-order reaction mathematical model.
    • Applied the model to existing experimental data from human volunteers.
    • Compared model predictions with experimental serum concentration-time data.
    Keywords:
    AMINOSALICYLIC ACIDBLOOD CHEMICAL ANALYSISINJECTIONS, INTRAVENOUSMETABOLISM

    Related Experiment Videos

  • Investigated a second-order model for high-concentration intravenous administration.

    • Main Results:

    • The three-reaction model accurately predicted PAS serum levels for oral administration across different preparations.
    • Model parameters explained variations in blood levels between different PAS formulations.
    • The model effectively described elimination after single IV infusions up to 11 mg/100 ml.
    • A second-order model was necessary to fit experimental data at higher IV concentrations.
    • Prolonged treatment with phenyl-p-aminosalicylate showed changes in elimination parameters.

    Conclusions:

    • A three-reaction mathematical model provides a robust framework for understanding PAS pharmacokinetics after oral administration.
    • Pharmacokinetic differences between PAS preparations can be quantitatively explained by model parameter variations.
    • PAS elimination kinetics exhibit dose-dependent behavior, requiring different models for low and high intravenous concentrations.
    • Changes in elimination parameters occur during prolonged treatment with phenyl-p-aminosalicylate.